Skip to main content

Zalbin

Generic name: albinterferon alfa-2b
Treatment for: Hepatitis C

Complete Response Letter for Zalbin BLA

Human Genome Sciences Receives Complete Response Letter from FDA on Zalbin BLA for Chronic Hepatitis C

ROCKVILLE, Md.--(BUSINESS WIRE)--Oct 5, 2010 - Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that, as expected, it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for 900-mcg Zalbin (albinterferon alfa-2b, known in Europe as Joulferon) dosed every two weeks for the treatment of chronic hepatitis C. HGS and Novartis have decided not to develop Zalbin further.

HGS, Human Genome Sciences and Zalbin are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of Human Genome Sciences' unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials and regulatory approvals, Human Genome Sciences' ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences' dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Contact: Human Genome Sciences, Inc.
Media:
Jerry Parrott, 301-315-2777
Vice President, Corporate Communications
or
Investors:
Claudine Prowse, Ph.D., 301-315-1785
Executive Director, Investor Relations
or
Peter Vozzo, 301-251-6003
Senior Director, Investor Relations

Posted: October 2010

Related articles

Zalbin (albinterferon alfa-2b) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.